Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 314 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infiltration Clear all
Recruiting Phase 2 Interventional

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

NCT02133196
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinoma
Interventions
Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Terminated Not applicable Interventional

Oxandrolone Rotator Cuff Trial

NCT03091075
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Oxandrolone, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
40 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Nebulized Albuterol on Donor Oxygenation

NCT00310401
View directory record Official record
Conditions
Brain Death, Organ Donor, Pulmonary Edema
Interventions
Albuterol, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
14 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 22, 2026, 9:38 AM EDT
Completed No phase listed Observational

Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure

NCT03225807
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS, Respiratory Distress Syndrome, Acute, Respiratory Insufficiency, Respiratory Distress Syndrome, Shock Lung, Severe Acute Respiratory Syndrome
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
8,692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 22, 2026, 9:38 AM EDT
Terminated Phase 1 Interventional

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

NCT06566092
View directory record Official record
Conditions
Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma, Melanoma, Rhabdomyosarcoma, Ewing Sarcoma
Interventions
LN-145/LN-144
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
6 Months to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • St. Petersburg, Florida • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Not applicable Interventional

Pain After Laparoscopic Cholecystectomy With Bilateral Tranversus Abdominis Plane (TAP) Block Versus Local Anesthetic Infiltration

NCT01204892
View directory record Official record
Conditions
Postoperative Pain
Interventions
TAP Block, Local infiltration
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 22, 2026, 9:38 AM EDT
Recruiting Not applicable Interventional

Assessment Intravenous Site Events During Outpatient Infusion Procedures With a Wireless Thermal Measurement Device During

NCT07009405
View directory record Official record
Conditions
IV Infiltration, IV Extravasation
Interventions
non-invasive thermal infusion site monitoring NTISM device
Device
Lead sponsor
Rhaeos, Inc.
Industry
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

NCT02360579
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Lifileucel
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Results available

TAP-patients With Robotic Assisted Lap Prostatectomy

NCT01582477
View directory record Official record
Conditions
Postsurgical Pain, Analgesia, Prostatectomy
Interventions
EXPAREL 20 mL, EXPAREL 40 mL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 22, 2026, 9:38 AM EDT
Terminated Phase 4 Interventional Results available

A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301

NCT01507220
View directory record Official record
Conditions
Bowel Obstruction
Interventions
morphine sulfate, bupivacaine liposome extended-release injectable suspension
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Comparative Study of Two Topical Anesthetics Prior to Fractional Nonablative Laser Treatment of the Face

NCT04523961
View directory record Official record
Conditions
Anesthesia, Local, Photodamaged Skin, Topical and Infiltration Anesthetic Toxicity
Interventions
2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion, 7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Not applicable Interventional

Nerve Blocks vs Local Injections for Post-op Pain Prevention in Laparoscopic Cholecystectomy in Children

NCT03022279
View directory record Official record
Conditions
Laparoscopic Cholecystectomy
Interventions
TAP Blocks, local wound infiltration
Procedure
Lead sponsor
Brian Wallace Gray
Other
Eligibility
8 Years to 17 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

NCT03176459
View directory record Official record
Conditions
C-Section, Pain Management
Interventions
Exparel + Bupivacaine, Bupivacaine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
12
States / cities
Loma Linda, California • Stanford, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

NCT02500576
View directory record Official record
Conditions
Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Pembrolizumab, Quality-of-Life Assessment, Therapeutic Tumor Infiltrating Lymphocytes
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 22, 2026, 9:38 AM EDT
Recruiting Phase 1 Interventional

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

NCT05483491
View directory record Official record
Conditions
Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Interventions
KK-LC-1 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Withdrawn Phase 4 Interventional

Liposomal Bupivacaine After Cesarean Delivery

NCT03907813
View directory record Official record
Conditions
Pain, Postoperative, Opioid Use
Interventions
Exparel, Saline infiltration
Drug · Other
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 22, 2026, 9:38 AM EDT
Terminated Not applicable Interventional

Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System

NCT03889093
View directory record Official record
Conditions
Hepatocellular Carcinoma, Secondary Malignant Neoplasm of Liver
Interventions
Yttrium-90
Other
Lead sponsor
University of Minnesota
Other
Eligibility
22 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 22, 2026, 9:38 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

NCT06237881
View directory record Official record
Conditions
Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms
Interventions
KSQ-001EX, Interleukin-2, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

NCT03853694
View directory record Official record
Conditions
Elective Cesarean Section, Pain Management
Interventions
50 mcg Duramorph+ EXPAREL + multi-modal pain regimen, 150 mcg Duramorph + multi-modal pain regimen, Exparel TAP + multi-modal pain regimen
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Stanford, California • Gainesville, Florida • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 22, 2026, 9:38 AM EDT
Recruiting Phase 1 Interventional

Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

NCT04772456
View directory record Official record
Conditions
Glioma
Interventions
Hyperpolarized 13C-Pyruvate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Not applicable Interventional

Study to Evaluate ACB Versus FNB Early Postoperative Period Functional Outcomes After TKA

NCT02218814
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Nerve Block
Interventions
Adductor Canal Block, Bupivacaine, Femoral Nerve Block, Bupivacaine
Procedure
Lead sponsor
George Macrinici
Other
Eligibility
40 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Joliet, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Early Phase 1 Interventional

Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer

NCT00527293
View directory record Official record
Conditions
Breast Cancer
Interventions
adjuvant therapy, 3-dimensional conformal radiation therapy, brachytherapy
Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
4
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 22, 2026, 9:38 AM EDT
Withdrawn Not applicable Interventional

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

NCT02944357
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
Interventions
Cisplatin, Gemcitabine Hydrochloride, Radical Cystectomy, Tumor Cell-Derived Vaccine Therapy
Drug · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Pembrolizumab

NCT02818920
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Neal Ready MD PhD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Rochester, Minnesota • Lebanon, New Hampshire • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 22, 2026, 9:38 AM EDT